Azilsartan: Current Evidence and Perspectives in Management of Hypertension
Joint Authors
Pradhan, Akshyaya
Sethi, Rishi
Tiwari, Ashish
Source
International Journal of Hypertension
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-11-03
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Hypertension continues to be global pandemic with huge mortality, morbidity, and financial burden on the health system.
Unfortunately, most patients with hypertension would eventually require two or more drugs in combination to achieve their target blood pressure (BP).
To this end, emergence of more potent antihypertensive drugs is a welcome sign.
Angiotensin receptor blockers (ARBs) are cornerstones of hypertension management in daily practice.
Among all ARBs, azilsartan is proven to be more potent in most of the head-to-head trials till date.
Azilsartan is the latest ARB approved for hypertension with greater potency and minimal side effects.
This review highlights the role of azilsartan in management of hypertension in the current era.
American Psychological Association (APA)
Pradhan, Akshyaya& Tiwari, Ashish& Sethi, Rishi. 2019. Azilsartan: Current Evidence and Perspectives in Management of Hypertension. International Journal of Hypertension،Vol. 2019, no. 2019, pp.1-8.
https://search.emarefa.net/detail/BIM-1165962
Modern Language Association (MLA)
Pradhan, Akshyaya…[et al.]. Azilsartan: Current Evidence and Perspectives in Management of Hypertension. International Journal of Hypertension No. 2019 (2019), pp.1-8.
https://search.emarefa.net/detail/BIM-1165962
American Medical Association (AMA)
Pradhan, Akshyaya& Tiwari, Ashish& Sethi, Rishi. Azilsartan: Current Evidence and Perspectives in Management of Hypertension. International Journal of Hypertension. 2019. Vol. 2019, no. 2019, pp.1-8.
https://search.emarefa.net/detail/BIM-1165962
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1165962